GlassScriptPhysician profile
Michael L Gross
NPI 1386701654
$46,581.74
in general payments reported to CMS, 2019-2025
82 companies · $2,404 in 2025
The $2,404 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $6,303 · 2021: $2,101 · 2022: $1,982 · 2023: $2,620 · 2024: $5,132 · 2025: $2,404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,934 · Consulting Fee: $1,685 · Education: $370 · Travel and Lodging: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,934.23 |
| Consulting Fee | $1,685.00 |
| Education | $369.87 |
| Travel and Lodging | $167.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $23,618.10 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Janssen Biotech, INC. | $5,411.40 | 2019-2025 | Tremfya, Simponi Aria |
| Ultragenyx Pharmaceutical INC. | $3,800.00 | 2020 | |
| Abbvie INC. | $2,236.51 | 2019-2025 | |
| Pfizer INC. | $1,475.38 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,407.57 | 2019-2025 | Trelegy Ellipta, Benlysta, Arexvy |
| Novartis Pharmaceuticals Corporation | $1,218.48 | 2019-2025 | |
| Edap Technomed INC | $735.00 | 2024 | |
| Lilly USA, LLC | $522.56 | 2019-2025 | Taltz, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $480.21 | 2019-2024 | Orencia |
| Ucb, INC. | $458.91 | 2019-2025 | Cimzia, Bimzelx |
| Actelion Pharmaceuticals US, INC. | $382.17 | 2019-2025 | Opsumit, Uptravi |
| Genzyme Corporation | $342.58 | 2019-2025 | |
| Horizon Therapeutics Plc | $335.09 | 2019-2023 | Krystexxa |
| Genentech USA, INC. | $251.79 | 2019-2025 | Actemra |
Show all 81 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.